MYCORRAY addresses a need identified by winegrowing sector SMEs for early, reliable, simultaneous identification of the 11 most relevant grapevine trunk fungi responsible for the most harmful diseases of grapevines, with crop losses estimated at thousands of millions of Euros in the EU alone every year.With an estimated commercial price of €1,500 per device and €30 per test, MYCORRAY will allow to effectively control grapevine trunk diseases, reducing the losses caused by these pathogens and their spread by means of immediate, precise and efficient interventions.The main innovations of MYCORRAY system are the application of the DNA microarray approach to the detection of different fungi involved in grapevine trunk diseases, and the development of a cost-effective, standalone (no PC needed) array reader for routine laboratory use, overcoming the limitations of the state of the art in terms of simultaneous detection, test and platform price, time-to-result, ease of use and interpretation and self-sufficiency.Additionally, a Guide for Best Practices will provide the most appropriate indications for reducing inoculum presence, avoiding new infections and reducing symptom development, based on the type and frequency of the pathogens found, improving disease control strategies.The consortium brings together a very diverse and representative sample of the three key main groups of potential customers of the technology (large wine producer, vine nursery and diagnostic test provider SMEs) and expert European SMEs for the development, manufacture and commercialization of MYCORRAY to guarantee the best exploitation route to a market worth an estimated €5,3 million over five years.